Phathom Pharmaceuticals Files 8-K

TL;DR

Phathom Pharma filed an 8-K, something happened, details TBD.

AI Summary

Phathom Pharmaceuticals, Inc. filed an 8-K on October 27, 2025, reporting an "Other Event" as of October 25, 2025. The filing does not contain specific details about the nature of this event, its financial implications, or any associated parties.

Why It Matters

This filing indicates a material event has occurred for Phathom Pharmaceuticals, but the lack of detail requires further investigation to understand its impact.

Risk Assessment

Risk Level: medium — The filing is an 8-K, which typically reports material events, but the lack of specific information creates uncertainty about potential risks.

Key Players & Entities

• Phathom Pharmaceuticals, Inc. (company) — Registrant
• October 25, 2025 (date) — Date of earliest event reported
• October 27, 2025 (date) — Date of report
• 100 Campus Drive, Suite 102 (address) — Principal executive offices
• Florham Park, New Jersey 07932 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share PHAT The Nasdaq Global Se

Filing Documents

• d62248d8k.htm (8-K) — 32KB
• 0001193125-25-250611.txt ( ) — 145KB
• phat-20251025.xsd (EX-101.SCH) — 3KB
• phat-20251025_lab.xml (EX-101.LAB) — 18KB
• phat-20251025_pre.xml (EX-101.PRE) — 11KB
• d62248d8k_htm.xml (XML) — 4KB

Forward Looking Statements

Forward Looking Statements This report contains forward-looking statements, including without limitation statements regarding: the potential clinical profile of VOQUEZNA; Phathom's estimates as to the size of certain patient populations and unmet need in GERD; Phathom's business strategy, goals, mission and vision; and Phathom's other expectations, forecasts and predictions as to future performance, results and likelihood of success. These statements involve known and unknown risks, uncertainties and other important factors that may cause Phathom's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: the unmet need for new treatment options in GERD may not be as high as Phathom anticipates; Phathom's estimates of the number of patients with GERD or subsets of such patients may not be accurate; the efficacy profile for VOQUEZNA in clinical practice may be different than the results discussed in this report; Phathom may encounter unexpected adverse side effects for VOQUEZNA in commercial use or future clinical development; Phathom may encounter setbacks in market acceptance for VOQUEZNA or commercialization that significantly impair Phathom's business strategy or efforts to achieve its goals, mission or vision; and any of the foregoing or other factors may negatively impact Phathom's ability to achieve its plans, goals, mission, vision and potential. For additional discussion of these and other risks, see the risk disclosure in Phathom's filings with the Securities and Exchange Commission ("SEC"), including its Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to revise or update this presentation to reflect events or circumstances after th

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHATHOM PHARMACEUTICALS, INC. Date: October 27, 2025 By: /s/ Anne Marie Cook Anne Marie Cook Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR